BioNxt Solutions Completes Shares for Debt Settlement

On September 19, 2025, BioNxt Solutions Inc., a bioscience company based in Vancouver, announced the successful closure of its debt settlement. This settlement involved an arm's length creditor and addressed an aggregate debt of $225,010 owed for services rendered to the company.

As part of the settlement, BioNxt issued 112,505 common shares at a price of CAD$1.00 per share and also made a cash payment of $112,505 to the creditor. The shares are subject to a four-month and one-day hold period in compliance with the Canadian Securities Exchange policies and Canadian securities law.

BioNxt, listed on the Canadian Securities Exchange and various international markets, continues to focus on drug delivery technologies and active pharmaceutical ingredient development.